Navigation Links
SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility
Date:8/4/2011

AMSTERDAM, The Netherlands, August 4, 2011 /PRNewswire/ --

SynCo Bio Partners B.V., one of the leading GMP contract manufacturers of biopharmaceuticals today announced that its aseptic filling facility is again fully operational and SynCo has produced and released the first drug product batches for its clients after the expansion of its Class A zone.  

The expansion of the Class A zone is an important milestone in SynCo's strategy in supporting its clients with new product launches in the US and the rest of the world.  SynCo's aseptic filling facility is able to fill and lyophilize a wide range of biopharmaceuticals which include proteins, monoclonal antibodies, polysaccharides, nucleic acids, aluminium containing vaccines, RNA and live biotherapeutics for clinical and market supply.

Announcing this upgrade, Pierre Warffemius, CEO of SynCo Bio Partners said:

"The expansion of the Class A zone is an excellent addition to SynCo Bio Partners' already state-of-the-art contract manufacturing facility in Amsterdam. SynCo is one of the few biopharmaceutical CMOs in the world with a recognized track record in both clinical and commercial manufacturing of both bulk drug substance and drug product and continuously invests in its facilities to achieve its goal: Trust us to make it right."

About SynCo Bio Partners B.V.

SynCo Bio Partners B.V. is a biopharmaceutical GMP Contract Manufacturing Organization located in Amsterdam, The Netherlands, licensed for clinical and commercial GMP manufacturing of Bulk Drug Substances and Drug Products.  As a truly global player, SynCo offers a fully integrated range of biopharmaceutical development and manufacturing services supporting small biotech to large pharmaceutical organizations worldwide from the earliest stages in process development, through pre-clinical and clinical trials, biologic license approval and market supply. For more information, please visit http://www.syncobiopartners.com


'/>"/>
SOURCE SynCo Bio Partners B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
2. SynCo Bio Partners and Versartis Expand Collaboration as Lead Product Enters into Clinical Trials
3. SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production
4. SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company
5. SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes
6. SynCo Bio Partners Increases its Capacities by Expanding its Quality Team
7. SynCo Bio Partners Wins Best Contract Manufacturing Organization 2009 ViE Award
8. INC Research and Debiopharm Group(TM) Announce Strategic Partnership
9. Hitachi partnership brings new tools and electron microscope reference center to Edmonton
10. Emerson Ecologics Expands Partnership With Metagenics, Announces National Distribution Agreement
11. HCCS Partners with American Association of Critical Care Nurses (AACN) to Offer Nurse Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only way to ... technology experience. All three tenets were on display at the 2nd Annual DrugDev User ... 40 sponsor, CRO and site organizations to discuss innovation and the future of clinical ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 /PRNewswire/ ... of genomic services and solutions with cutting edge next-generation ... has completed a USD $75 Million [515 Million RMB] ... CMB International Capital Management ( Shenzhen ) ... Ltd. ("SDIC Innovation") and Shanghai Sigma Square Investment Center ...
Breaking Biology Technology:
(Date:11/17/2016)... Nov. 17, 2016  AIC announces that it has just released a new white ... require high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
(Date:11/14/2016)... Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a ... challenging operating environments, announced its results for the third ... conference call to discuss these results on November 15, ... Key Recent Accomplishments The ... Vislink Communication Systems. The purchase is expected to close ...
Breaking Biology News(10 mins):